No FDA meeting or breakthrough-therapy update on any psilocybin GAD/AUD program will emerge from today's early-phase trials within 12 weeks.

Early-phase clinical trials testing psilocybin (the active compound in 'magic mushrooms') for generalized anxiety disorder and alcohol use disorder are still in the earliest stages — they're mainly checking whether the drug is safe and tolerable, not whether it works. The FDA (the US drug regulator) doesn't hold formal meetings or grant special fast-track designations based on this kind of preliminary data. Meaningful regulatory conversations are still years away.

The psilocybin GAD and AUD signals are safety/tolerability stage — years from regulatory dialogue. Agencies don't engage preliminary data.